PCSK9 and Stroke: Evolocumab consistently demonstrated a statistically significant reduction in LDL-C and, in several large-scale trials (such as Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)), also showed a reduction in cardiovascular events, including myocardial infarction and stroke.